13.19
+0.44(+3.45%)
Currency In USD
| Previous Close | 12.75 |
| Open | 12.9 |
| Day High | 14.17 |
| Day Low | 12.3 |
| 52-Week High | 20.4 |
| 52-Week Low | 3.44 |
| Volume | 159,168 |
| Average Volume | 1.46M |
| Market Cap | 104.94M |
| PE | -2.52 |
| EPS | -5.23 |
| Moving Average 50 Days | 8.52 |
| Moving Average 200 Days | 7.59 |
| Change | 0.44 |
If you invested $1000 in Biodesix, Inc. (BDSX) since IPO date, it would be worth $51.48 as of February 21, 2026 at a share price of $13.19. Whereas If you bought $1000 worth of Biodesix, Inc. (BDSX) shares 5 years ago, it would be worth $28.75 as of February 21, 2026 at a share price of $13.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 11:00 AM GMT
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the clo
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
GlobeNewswire Inc.
Jan 12, 2026 11:00 AM GMT
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
GlobeNewswire Inc.
Dec 03, 2025 1:22 PM GMT
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treat